Skip to main content
Terug
Watch Compare

Pasithea Therapeutics Corp.

Datakwaliteit: 83%
Ook genoteerd als KTTAW Nasdaq
KTTA
Nasdaq Manufacturing Chemicals
€ 0,74
▼ € 0,03 (-3,39%)
Marktkapitalisatie: 18,46 M
Prijs
€ 0,74
Marktkapitalisatie
18,46 M
Dagbereik
€ 0,70 — € 0,78
52-Weeksbereik
€ 0,28 — € 3,79
Volume
2.580.287
Openen € 0,73
50D / 200D Gem.
€ 0,80
7,23% below
50D / 200D Gem.
€ 0,81
8,78% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -15,21 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-149,19%
Onder sectorgemiddelde (-53,41%)
ROIC-119,72%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio4,02
Interest CoverageN/A

Waardering

PE (TTM)
-0,90
Boven sectorgemiddelde (-1,48)
P/B Ratio1,51
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B 1,5 1,6
ROE % -149,2 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

PSIL logo PSIL AdvisorShares Psychedelics ETF
1,08% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -20,43 M
ROE -149,19% ROA -133,34%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -15,21 M
ROIC -119,72% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,02
Interest Coverage N/A Asset Turnover N/A
Working Capital 4,15 M Tangible Book Value 4,11 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,90 Forward P/E N/A
P/B Ratio 1,51 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -82,41%
Market Cap 18,46 M Enterprise Value 14,34 M
Per Share
EPS (Diluted TTM) -2,91 Revenue / Share N/A
FCF / Share -0,61 OCF / Share -0,61
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 74,47%
SBC-Adj. FCF -15,57 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 486.559,0 15.062,0
Net Income -20,43 M -13,90 M -15,96 M -13,94 M -2,17 M
EPS (Diluted) -2,91 -0,42 -0,42 -0,53 —
Gross Profit — — — — -2.213,0
Operating Income -20,86 M -14,25 M -15,98 M -14,82 M -4,51 M
EBITDA — — — — —
R&D Expenses 7,98 M 7,20 M 8,10 M 2,67 M —
SG&A Expenses — 7,05 M 7,88 M 12,52 M 4,51 M
D&A — — — — —
Interest Expense — — — 102,0 -508,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 60,24 M 16,06 M 26,12 M 45,18 M 53,32 M
Total Liabilities 5,02 M 1,28 M 2,72 M 2,68 M 1,90 M
Shareholders' Equity 55,22 M 14,78 M 23,40 M 42,50 M 51,42 M
Total Debt — — — — —
Cash & Equivalents 55,16 M 6,92 M 16,33 M 33,15 M 52,97 M
Current Assets 56,46 M 7,37 M 16,69 M 34,08 M 53,30 M
Current Liabilities 4,97 M 1,12 M 2,63 M 1,88 M 447.280,0